Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment

Journal of Clinical Psychiatry

Volumn 76, Issue 11, 2015, Pages e1417-e1423

  Vandenberghe, Frederik ^a   Gholam Rezaee, Mehdi ^b   Saigí Morgui, Núria ^a   Delacrétaz, Aurélie ^a   Choong, Eva ^a   Solida Tozzi, Alessandra ^c   Kolly, Stéphane ^c   Thonney, Jacques ^c   Gallo, Sylfa Fassassi ^c   Hedjal, Ahmed ^c   Ambresin, Anne Emmanuelle ^e   Von Gunten, Armin ^d   Conus, Philippe ^c   Eap, Chin B ^a,f  

^a Hopital de Cery   (Switzerland)

^b Center for Psychiatric Epidemiology and Psychopathology   (Switzerland)

^c Service of General Psychiatry   (Switzerland)

^d Department of Psychiatry   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LITHIUM; MIRTAZAPINE; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; VALPROIC ACID; NEUROLEPTIC AGENT; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; APPETITE; ARTICLE; BIPOLAR DISORDER; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OBSERVATIONAL STUDY; PHYSICAL ACTIVITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK BENEFIT ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE; WEIGHT GAIN; BODY WEIGHT; COMORBIDITY; DRUG EFFECTS; MENTAL DISORDERS; OVERWEIGHT; PROGNOSIS; TIME;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; COMORBIDITY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL DISORDERS; METABOLIC SYNDROME X; MIDDLE AGED; OVERWEIGHT; PROGNOSIS; PSYCHOTROPIC DRUGS; TIME FACTORS; WEIGHT GAIN;

EID: 84958258979     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.14m09358     Document Type: Article

References (30)

1. De Hert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24(6):412-424. doi:10.1016/j.eurpsy.209.01.05 PubMed
2. Newcomer JW. Metabolic syndrome and mental illness. Am J Manag Care. 2007;13(suppl):S170-S177. PubMed
3. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696. PubMed
4. Laimer M, Kramer-Reinstadler K, Rauchenzauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry. 2006;67(3):421-424. doi:10.408/JCP.v67n0313 PubMed
5. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114-126. doi:10.1038/nrendo.201.156 PubMed
6. Vehof J, Risselada AJ, Al Hadithy AF, et al. Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. Psychopharmacology (Berl). 2011;216(2):257-265. doi:10.107/s0213-01-21-x PubMed
7. Choong E, Quteineh L, Cardinaux JR, et al; ODEX team. Influence of CRTC1 polymorphisms on body mass index and fat mass in psychiatric patients and the general adult population. JAMA Psychiatry. 2013;70(10):1011-1019. doi:10.101/jamapsychiatry.2013.187 PubMed
8. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care. 2004;27(2):596-601. doi:10.237/diacare.27.2.596 PubMed
9. Hoffmann VP, Case M, Stauffer VL, et al. Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials. J Clin Psychopharmacol. 2010;30(6):656-660. doi:10.1097/JCP.0b013e3181faf670 PubMed
10. Lipkovich I, Jacobson JG, Hardy TA, et al. Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry. 2008;8(1):78. doi:10.186/1471-24X-8-78 PubMed
11. Lipkovich I, Citrome L, Perlis R, et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol. 2006;26(3):316-320. doi:10.1097/01.jcp.021916.810.1c PubMed
12. Ascher-Svanum H, Zhu B, Faries DE, et al. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence. 2008;2:67-77. doi:10.2147/PA.S2940 PubMed
13. Kane JM, Osuntokun O, Kryzhanovskaya LA, et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry. 2009;70(4):572-581. doi:10.408/JCP.08m0421 PubMed
14. Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week doubleblind study in patients with schizophrenia. Am J Psychiatry. 2005;162(10):1879-1887. doi:10.176/api.ajp.162.10.1879 PubMed
15. Tran PV, Hamilton SH, Kuntz AJ, et al. Doubleblind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997;17(5):407-418. doi:10.1097/04714-19710-010 PubMed
16. Choong E, Solida A, Lechaire C, et al. Follow-up of the metabolic syndrome induced by atypical antipsychotics: recommendations and pharmacogenetics perspectives [article in French]. Rev Med Suisse. 2008;4(171):1994-1996, 1998-1999. PubMed
17. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. PubMed
18. Mitchell AJ, Vancampfort D, De Herdt A, et al. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull. 2013;39(2):295-305. doi:10.1093/schbul/sbs082 PubMed
19. Falissard B, Mauri M, Shaw K, et al. The METEOR study: frequency of metabolic disorders in patients with schizophrenia: focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol. 2011;26(6):291-302. doi:10.1097/YIC.0b013e32834a5bf6 PubMed
20. Choong E, Bondolfi G, Etter M, et al. Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. J Psychiatr Res. 2012;46(4):540-548. doi:10.1016/j.jpsychires.2012.01.014 PubMed
21. Greil W, Häberle A, Schuhmann T, et al. Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland. Swiss Med Wkly. 2013;143:w13772. PubMed
22. Rondanelli M, Sarra S, Antoniello N, et al. No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease. Minerva Med. 2006;97(2):147-151. PubMed
23. Zheng L, Mack WJ, Dagerman KS, et al. Metabolic changes associated with secondgeneration antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry. 2009;166(5):583-590. doi:10.176/api.ajp.208.08081218 PubMed
24. Kinon BJ, Kaiser CJ, Ahmed S, et al. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 2005;25(3):255-258. doi:10.1097/01.jcp.0161501.65890.2 PubMed
25. Verma SK, Subramaniam M, Liew A, et al. Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry. 2009;70(7):997-1000. doi:10.408/JCP.08m04508 PubMed
26. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-1773. doi:10.101/jama.209.1549 PubMed
27. Case M, Treuer T, Karagianis J, et al. The potential role of appetite in predicting weight changes during treatment with olanzapine. BMC Psychiatry. 2010;10(1):72. doi:10.186/1471-24X-10-72 PubMed
28. Daumit GL, Dickerson FB, Wang NY, et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med. 2013;368(17):1594-1602. doi:10.1056/NEJMoa1214530 PubMed
29. Pérez-Iglesias R, Martínez-García O, Pardo-Garcia G, et al. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. Int J Neuropsychopharmacol. 2014;17(1):41-51. doi:10.1017/S14614571301053 PubMed
30. Novick D, Haro JM, Perrin E, et al. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol. 2009;19(8):542-550. doi:10.1016/j.euroneuro.209.03.03 PubMed